Medindia

X

Pharmacyclics Announces Presentation of Results From Phase I Trial of Its First-in-Human Btk Inhibitor: PCI-32765

Sunday, June 6, 2010 General News J E 4
Advertisement

N

Complete Response

Partial Response

Stable Disease

Progressive Disease

Not Evaluable*

Evaluable

RR%

ORR %

ITT**

Chronic/Small  Lymphocytic Leukemia (CLL/SLL)

13

1

8

2

0

2

82%

(9/11)

69%

(9/13)

Mantle Cell (MCL)

4

1

2

1

0

75%

(3/4)

75%

(3/4)

Diffuse Large B Cell Lymphoma (DLBCL)

6

1

1

4

17%

(1/6)

17%

(1/6)

Follicular Lymphoma (FL)

13

3

4

4

2

27%

(3/11)

23%

(3/13)

Marginal

4

1

1

1

1

33%

(1/3)

25%

(1/4)

Total

40

2

15

9

9

5

49%

(17/35)

43%

(17/40)

* Includes those patients who did not complete 2 cycles of therapy and withdrew from study

** Includes all “Intent To Treat” patients

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Queen Meg, Registered Nurses, and Everyday Califor...
S
Onyx Pharmaceuticals' Carfilzomib Continues to Dem...